Leslie Burnett

Prof. Leslie Burnett

Garvan Institute of Medical Research, Darlinghurst, Australia
+2
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1996 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MTMei‐Heng Tan
Mei‐Heng Tan
CCChris A Commens
Chris A Commens
LBLeslie Burnett
Leslie Burnett
PSPeter J Snitch
Peter J Snitch

21 November 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
EKEdwin P. Kirk
Edwin P. Kirk
MDMartin Delatycki
Martin Delatycki
AAAlison D. Archibald
Alison D. Archibald
ETErin Tutty
Erin Tutty
JCJade Caruana
Jade Caruana
NLNigel George Laing
Nigel George Laing
Genomic sequencing technology allows for identification of reproductive couples with an increased chance, as compared with that in the general population, of having a child with an autosomal recessive or X-linked genetic condition. We investigated the feasibility, acceptability, and outcomes of a nationwide, couple-based genetic carrier screening program in Australia as part of the Mackenzie's Mission project. Health care providers offered screening to persons before pregnancy or early in pregnancy. The results obtained from testing at least 1281 genes were provided to the reproductive couples. We aimed to ascertain the psychosocial effects on participants, the acceptability of screening to all participants, and the reproductive choices of persons identified as having an increased chance of having a child with a condition for which we screened. Among 10,038 reproductive couples enrolled in the study, 9107 (90.7%) completed screening, and 175 (1.9%) were newly identified as having an increased chance of having a child with a genetic condition for which we screened. These conditions involved pathogenic variants in 90 different genes; 74.3% of the conditions were autosomal recessive. Three months after receiving the results, 76.6% of the couples with a newly identified increased chance had used or planned to use reproductive interventions to avoid having an affected child. Those newly identified as having an increased chance had greater anxiety than those with a low chance. The median level of decisional regret was low in all result groups, and 98.9% of participants perceived screening to be acceptable. Couple-based reproductive genetic carrier screening was largely acceptable to participants and was used to inform reproductive decision making. The delivery of screening to a diverse and geographically dispersed population was feasible. (Funded by the Medical Research Future Fund of the Australian government; ClinicalTrials.gov number, NCT04157595.).

12 January 2021 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
AMAmali Mallawaarachchi
Amali Mallawaarachchi
BLBen Lundie
Ben Lundie
YHYvonne Hort
Yvonne Hort
NSNicole Schonrock
Nicole Schonrock
SSSarah R. Senum
Sarah R. Senum
TFTimothy J. Furlong
Timothy J. Furlong

Verified
Journal Article
Open access
PDF file
AAAlison D. Archibald
Alison D. Archibald
BMBelinda J. McClaren
Belinda J. McClaren
JCJade Caruana
Jade Caruana
ETErin Tutty
Erin Tutty
EKEmily A. King
Emily A. King
TTThe Mackenzie’s Mission Study Team
The Mackenzie’s Mission Study Team
Reproductive genetic carrier screening (RGCS) provides people with information about their chance of having children with autosomal recessive or X-linked genetic conditions, enabling informed reproductive decision-making. RGCS is recommended to be offered to all couples during preconception or in early pregnancy. However, cost and a lack of awareness may prevent access. To address this, the Australian Government funded Mackenzie’s Mission—the Australian Reproductive Genetic Carrier Screening Project. Mackenzie’s Mission aims to assess the acceptability and feasibility of an easily accessible RGCS program, provided free of charge to the participant. In study Phase 1, implementation needs were mapped, and key study elements were developed. In Phase 2, RGCS is being offered by healthcare providers educated by the study team. Reproductive couples who provide consent are screened for over 1200 genes associated with >750 serious, childhood-onset genetic conditions. Those with an increased chance result are provided comprehensive genetic counseling support. Reproductive couples, recruiting healthcare providers, and study team members are also invited to complete surveys and/or interviews. In Phase 3, a mixed-methods analysis will be undertaken to assess the program outcomes, psychosocial implications and implementation considerations alongside an ongoing bioethical analysis and a health economic evaluation. Findings will inform the implementation of an ethically robust RGCS program.

1 April 2003 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
KBK Barlow-Stewart
K Barlow-Stewart
LBLeslie Burnett
Leslie Burnett
APA Proos
A Proos
VHV Howell
V Howell
FHF Huq
F Huq
HAH Aizenberg
H Aizenberg

1 January 2015 in The Application of Clinical Genetics
Verified
Journal Article
Open access
RLRaelia M Lew
Raelia M Lew
LBLeslie Burnett
Leslie Burnett
MDMartin B Delatycki
Martin B Delatycki
APAnné L Proos
Anné L Proos
Tay-Sachs disease (TSD) is a fatal, recessively inherited neurodegenerative condition of infancy and early childhood. Although rare in most other populations, the carrier frequency is one in 25 in Ashkenazi Jews. Australian high-school-based TSD preconception genetic screening programs aim to screen, educate, and optimize reproductive choice for participants. These programs have demonstrated high uptake, low psychological morbidity, and have been shown to result in fewer than expected Jewish TSD-affected births over 18 years of operation. The majority of Jewish individuals of reproductive age outside of the high school screening program setting in Australia have not accessed screening. Recent recommendations advocate supplementing the community high school screening programs with general practitioner- and obstetrician-led genetic screening of Ashkenazi Jewish individuals for TSD and other severe recessive diseases for which this group is at risk. Massively parallel DNA sequencing is expected to become the testing modality of choice over the coming years.